The Franklin will be holding a seminar given by Eduardo da Veiga Beltrame on Wednesday the 18th December from 10:30-11:30.
To watch the seminar online, please sign up on the Eventbrite.
Further details on this seminar are included below.
Talk title:
New research directions in single cell omics and artificial intelligence
Abstract:
One of the most exciting consequences of the accessibility of single cell omics technologies is their use in new experimental designs. Beyond atlases, longitudinal studies with many timepoints are also yielding unprecedented volumes and formats of data. Driven by steadily decreasing sequencing costs and streamlined experimental workflows, single cell omics technologies, (especially single cell RNA sequencing) are now widely used from basic biological research to drug discovery and clinical studies. I will present an overview of the emerging data landscape in the field of single cell omics, together with novel clinical study designs enabled by lowering cost and complexity barriers. I will discuss emerging research directions for working with these growing volumes of single cell omics data, together with my research interests at the newly established department of computational biology at MBZUAI, and exciting opportunities at the intersection of artificial intelligence applied to biological data.
Biography:
Eduardo da Veiga Beltrame is an Assistant Professor of Computational Biology at Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). His main research interest is on developing methods and tools for working with biological data generated by single cell omics technologies and corresponding applications in advancing precision medicine. Beltrame holds a Ph.D. in bioengineering from Caltech, where his primary research focus was on the development of experimental and computational methods and tools for single cell RNA sequencing and their application to answering biological questions. Prior to joining MBZUAI, he was bioinformatics lead at ImYoo (https://imyoo.health), a biotechnology startup spun out of Caltech research that executes decentralized immune studies using single cell omics. Before ImYoo, Beltrame was founding scientist at Retro Biosciences, a biotechnology startup developing ageing-related therapeutics. He is also a visiting scholar at UC Berkeley School of Education, working on a research partnership with innovative STEM education programs in Brazil.